
Commentary|Videos|March 15, 2026
How ctDNA Testing is Changing Lymphoma Treatment
Author(s)Hua-Jay "Jeff" Cherng, MD
Fact checked by: Paige Britt
MRD testing promises sharper DLBCL response tracking than PET scans, cutting false positives, biopsies, and guiding therapy as trials catch up.
Advertisement
In an interview with Targeted Oncology, Hua-Jay “Jeff” Cherng, MD, assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology at the Columbia University Irving Medical Center, discussed how circulating tumor DNA testing is changing the way doctors monitor response to treatment compared with traditional PET scans.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Iberdomide, the First CELMoD for Relapsed/Refractory Multiple Myeloma
2
How the Immune System Drives Nerve Growth in TNBC
3
AMH Testing Predicts Chemotherapy Benefit in RxPONDER Breast Cancer
4
FAQ: When and How to Discontinue Lenalidomide Maintenance in Multiple Myeloma
5


































